 |
Corporate News
24-Dec-24
|
|
|
|
|
|
|
|
|
|
|
|
Biocon and Zentiva receive Decentralized Procedure approval for Liraglutide
|
|
|
|
|
|
|
|
Biocon announced that the company and it European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza® to treat Type-2 Diabetes and
Saxenda® used in the treatment of weight management.
|
|
|
|
Previous News |
Biocon consolidated net profit rises 472.91% in the December 2025 quarter
(
Results
-
Announcements
13-Feb-26
07:34
)
|
|
|
Biocon Ltd up for five straight sessions
(
Hot Pursuit
-
04-Feb-26
13:00
)
|
|
|
Biocon Ltd rises for third straight session
(
Hot Pursuit
-
16-Jan-26
13:05
)
|
|
|
Biocon concludes QIP issue of Rs 4,150 cr
(
Corporate News
-
15-Jan-26
12:10
)
|
|
|
Biocon to hold board meeting
(
Corporate News
-
14-Jan-26
10:04
)
|
|
|
Stock Alert: Biocon, Senco Gold, Jubilant Foodworks, Titan Company
(
Market Commentary
-
Stock Alert
07-Jan-26
07:58
)
|
|
|
Biocon Biologics to introduce three new biosimilar oncology assets
(
Corporate News
-
06-Jan-26
19:59
)
|
|
|
Biocon Ltd soars 0.1%, rises for fifth straight session
(
Hot Pursuit
-
23-Dec-25
13:00
)
|
|
|
Biocon arm secures global rights for Hulio from Fujifilm Kyowa Kirin Biologics Co
(
Hot Pursuit
-
23-Dec-25
11:23
)
|
|
|
Biocon launches its diabetes & obesity treatment drugs in Netherlands
(
Hot Pursuit
-
15-Dec-25
09:45
)
|
|
|
Biocon launches GLP-1 peptide, Liraglutide in the Netherlands
(
Corporate News
-
15-Dec-25
09:09
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|